Jacky Y Suen

List of Publications by Year
in descending order

94 papers	2,708 citations	257450 24 h-index	243625 44 g-index

100 all docs	100 docs citations	100 times ranked	3076 citing authors

#	Article	IF	Citations
1	Beneficial Effect of Prone Positioning During Venovenous Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019*. Critical Care Medicine, 2022, 50, 275-285.	0.9	28
2	Mid and long-term neurological and neuropsychiatric manifestations of post-COVID-19 syndrome: A meta-analysis. Journal of the Neurological Sciences, 2022, 434, 120162.	0.6	335
3	Prone position during venovenous extracorporeal membrane oxygenation: survival analysis needed for a time-dependent intervention. Critical Care, 2022, 26, 39.	5.8	2
4	Exploration of the Utility of Speckle-Tracking Echocardiography During Mechanical Ventilation and Mechanical Circulatory Support. , 2022, 4, e0666.		3
5	Impact of reninâ€“angiotensinâ€“aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study. BMC Cardiovascular Disorders, 2022, 22, 123.	1.7	4
6	Recovery of organ-specific tissue oxygen delivery at restrictive transfusion thresholds after fluid treatment in ovine haemorrhagic shock. Intensive Care Medicine Experimental, 2022, 10, 12.	1.9	1
7	Non-Invasive Multimodal Neuromonitoring in Non-Critically Ill Hospitalized Adult Patients With COVID-19: A Systematic Review and Meta-Analysis. Frontiers in Neurology, 2022, 13, 814405.	2.4	4
8	Venovenous extracorporeal membrane oxygenation in patients with acute covid-19 associated respiratory failure: comparative effectiveness study. BMJ, The, 2022, 377, e068723.	6.0	63
9	Hypothermic Ex Vivo Perfusion of Donor Hearts can Safely Preserve Postâ€transplant Cardiac Function in Sheep for 8 Hours. FASEB Journal, 2022, 36, .	0.5	0
10	Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis. Critical Care, 2022, 26, 141.	5.8	9
11	Differential Protein Expression among Two Different Ovine ARDS Phenotypesâ€”A Preclinical Randomized Study. Metabolites, 2022, 12, 655.	2.9	1
12	PAR2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate EGFR. British Journal of Pharmacology, 2021, 178, 913-932.	5.4	21
13	Assessing potential for aortoiliac vascular injury from venoarterial extracorporeal membrane oxygenation cannulae: An in vitro particle image velocimetry study. Artificial Organs, 2021, 45, E14-E25.	1.9	4
14	The discovery of biological subphenotypes in ARDS: a novel approach to targeted medicine?. Journal of Intensive Care, 2021, 9, 14.	2.9	13
15	Peritransplant Cardiometabolic and Mitochondrial Function: The Missing Piece in Donor Heart Dysfunction and Graft Failure. Transplantation, 2021, 105, 496-508.	1.0	3
16	Expression of protease activated receptor-2 is reduced in renal cell carcinoma biopsies and cell lines. PLoS ONE, 2021, 16, e0248983.	2.5	3
17	Studying the Endothelial Glycocalyx in vitro: What Is Missing?. Frontiers in Cardiovascular Medicine, 2021, 8, 647086.	2.4	20
18	Extracorporeal Membrane Oxygenation-Induced Hemolysis: An In Vitro Study to Appraise Causative Factors. Membranes, 2021, 11, 313.	3.0	12

#	Article	IF	Citations
19	The use of extracorporeal membrane oxygenation in children with acute fulminant myocarditis. Clinical and Experimental Pediatrics, 2021, 64, 188-195.	2.2	10
20	An Ovine Model of Hemorrhagic Shock and Resuscitation, to Assess Recovery of Tissue Oxygen Delivery and Oxygen Debt, and Inform Patient Blood Management. Shock, 2021, 56, 1080-1091.	2.1	4
21	An appraisal of respiratory system compliance in mechanically ventilated covid-19 patients. Critical Care, 2021, 25, 199.	5.8	21
22	Ethical factors determining ECMO allocation during the COVID-19 pandemic. BMC Medical Ethics, 2021, 22, 70.	2.4	22
23	Ischemic and Hemorrhagic Stroke Among Critically Ill Patients With Coronavirus Disease 2019: An International Multicenter Coronavirus Disease 2019 Critical Care Consortium Study*. Critical Care Medicine, 2021, 49, e1223-e1233.	0.9	20
24	Compromised right ventricular contractility in an ovine model of heart transplantation following 24Âh donor brain stem death. Pharmacological Research, 2021, 169, 105631.	7.1	2
25	001â€...Neurological manifestations of coronavirus disease 2019: a comprehensive review. , 2021, , .		0
26	Coagulation Dysfunction in Acute Respiratory Distress Syndrome and Its Potential Impact in Inflammatory Subphenotypes. Frontiers in Medicine, 2021, 8, 723217.	2.6	11
27	035â€...Case-control study of risk factors for stroke among critically-ill patients with SARS-CoV-2: an analysis of the COVID-19 critical care consortium (CCCC) global registry. , 2021, , .		0
28	Neurological Manifestations of Coronavirus Disease 2019: A Comprehensive Review and Meta-Analysis of the First 6 Months of Pandemic Reporting. Frontiers in Neurology, 2021, 12, 664599.	2.4	19
29	Anti-thrombogenic Surface Coatings for Extracorporeal Membrane Oxygenation: A Narrative Review. ACS Biomaterials Science and Engineering, 2021, 7, 4402-4419.	5.2	39
30	Design and Rationale of a Prospective International Follow-Up Study on Intensive Care Survivors of COVID-19: The Long-Term Impact in Intensive Care Survivors of Coronavirus Disease-19â€“AFTERCOR. Frontiers in Medicine, 2021, 8, 738086.	2.6	2
31	Extracorporeal Membrane Oxygenation Cannulae-related Infection. ASAIO Journal, 2021, Publish Ahead of Print, .	1.6	1
32	Therapeutic Inhibition of Acid-Sensing Ion Channel 1a Recovers Heart Function After Ischemiaâ€“Reperfusion Injury. Circulation, 2021, 144, 947-960.	1.6	40
33	Acute Immune Response in Venoarterial and Venovenous Extracorporeal Membrane Oxygenation Models of Rats. ASAIO Journal, 2021, 67, 546-553.	1.6	10
34	An innovative ovine model of severe cardiopulmonary failure supported by veno-arterial extracorporeal membrane oxygenation. Scientific Reports, 2021, 11, 20458.	3.3	4
35	Characterizing preclinical subâ€phenotypic models of acute respiratory distress syndrome: An experimental ovine study. Physiological Reports, 2021, 9, e15048.	1.7	13
36	Assessment of 28-Day In-Hospital Mortality in Mechanically Ventilated Patients With Coronavirus Disease 2019: An International Cohort Study. , 2021, 3, e0567.		4

#	Article	IF	Citations
37	Abstract 10482: Renin-Angiotensin-Aldosterone System Inhibition is Associated with Reduced In-Hospital Mortality in Critically Ill Covid-19 Patients with Pre-Existing Hypertension. Circulation, 2021, 144, .	1.6	0
38	A clinically relevant sheep model of orthotopic heart transplantation 24Âh after donor brainstem death. Intensive Care Medicine Experimental, 2021, 9, 60.	1.9	1
39	Hypothermic Ex Vivo Perfusion: Protecting the Donor Heart and the Recipient. ASAIO Journal, 2020, 66, e99-e99.	1.6	0
40	The effect of hyperoxia on inflammation and platelet responses in an ex vivo extracorporeal membrane oxygenation circuit. Artificial Organs, 2020, 44, 1276-1285.	1.9	9
41	Heart Transplantation From Brain Dead Donors: A Systematic Review of Animal Models. Transplantation, 2020, 104, 2272-2289.	1.0	7
42	Reply to Zhang and Hei: Mesenchymal Stem Cellâ€“derived Exosomes: Are They Another Therapeutic Method for Extracorporeal Membrane Oxygenationâ€“supported Acute Respiratory Distress Syndrome?. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1603-1604.	5.6	0
43	Donor brain stem death and cardiac transplantation causes mitochondrial dyscoupling and oxidative stress. Australian Critical Care, 2020, 33, S31.	1.3	0
44	Ex vivo models for research in extracorporeal membrane oxygenation: a systematic review of the literature. Perfusion (United Kingdom), 2020, 35, 38-49.	1.0	5
45	Viability of Mesenchymal Stem Cells in an Ex Vivo Circulation System. ASAIO Journal, 2020, 66, 433-440.	1.6	5
46	ECMO use in COVID-19: lessons from past respiratory virus outbreaksâ€”a narrative review. Critical Care, 2020, 24, 301.	5.8	56
47	(-)-Noradrenaline sensitivity, contractility and mitochondrial function in an ovine model of brain stem death and transplantation. Journal of Molecular and Cellular Cardiology, 2020, 140, 48.	1.9	0
48	Combined Mesenchymal Stromal Cell Therapy and Extracorporeal Membrane Oxygenation in Acute Respiratory Distress Syndrome. A Randomized Controlled Trial in Sheep. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 383-392.	5.6	27
49	Current Understanding of Leukocyte Phenotypic and Functional Modulation During Extracorporeal Membrane Oxygenation: A Narrative Review. Frontiers in Immunology, 2020, 11, 600684.	4.8	14
50	Design and rationale of the COVID-19 Critical Care Consortium international, multicentre, observational study. BMJ Open, 2020, 10, e041417.	1.9	17
51	Heart failure supported by veno-arterial extracorporeal membrane oxygenation (ECMO): a systematic review of pre-clinical models. Intensive Care Medicine Experimental, 2020, 8, 16.	1.9	7
52	Proteaseâ€activated receptor 2 does not contribute to renal inflammation or fibrosis in the obstructed kidney. Nephrology, 2019, 24, 983-991.	1.6	3
53	Extracorporeal membrane oxygenation (ECMO) and the acute respiratory distress syndrome (ARDS): a systematic review of pre-clinical models. Intensive Care Medicine Experimental, 2019, 7, 18.	1.9	17
54	Low flow rate alters haemostatic parameters in an ex-vivo extracorporeal membrane oxygenation circuit. Intensive Care Medicine Experimental, 2019, 7, 51.	1.9	45

#	Article	IF	Citations
55	Hurdles to Cardioprotection in the Critically Ill. International Journal of Molecular Sciences, 2019, 20, 3823.	4.1	6
56	Pre-clinical study protocol: Blood transfusion in endotoxaemic shock. MethodsX, 2019, 6, 1124-1132.	1.6	1
57	Pharmacological inhibition of proteaseâ€activated receptorâ€2 reduces crescent formation in rat nephrotoxic serum nephritis. Clinical and Experimental Pharmacology and Physiology, 2019, 46, 456-464.	1.9	8
58	Mesenchymal stem cells may ameliorate inflammation in an ex vivo model of extracorporeal membrane oxygenation. Perfusion (United Kingdom), 2019, 34, 15-21.	1.0	16
59	Effect of ex vivo extracorporeal membrane oxygenation flow dynamics on immune response. Perfusion (United Kingdom), 2019, 34, 5-14.	1.0	16
60	Endothelialized flow models for blood transfusion research. Haematologica, 2019, 104, 428-434.	3.5	2
61	Neuron-Specific Enolase and Matrix Metalloproteinase 9 Signal Perioperative Silent Brain Infarction During or After Transcatheter Aortic Valve Implantation. American Journal of Cardiology, 2019, 123, 434-439.	1.6	5
62	Recruitment manoeuvres dislodge mucus towards the distal airways in an experimental model of severe pneumonia. British Journal of Anaesthesia, 2019, 122, 269-276.	3.4	4
63	Administration of mesenchymal stem cells during ECMO results in a rapid decline in oxygenator performance. Thorax, 2019, 74, 194-196.	5.6	27
64	A Potent Antagonist of Protease-Activated Receptor 2 That Inhibits Multiple Signaling Functions in Human Cancer Cells. Journal of Pharmacology and Experimental Therapeutics, 2018, 364, 246-257.	2.5	50
65	Differential immunological profiles herald magnetic resonance imaging-defined perioperative cerebral infarction. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628641875949.	3.5	5
66	Inflammation and lung injury in an ovine model of fluid resuscitated endotoxemic shock. Respiratory Research, 2018, 19, 231.	3.6	23
67	Transfusion of packed red blood cells at the end of shelf life is associated with increased risk of mortality â€“ a pooled patient data analysis of 16 observational trials. Haematologica, 2018, 103, 1542-1548.	3.5	29
68	Biased Signaling by Agonists of Protease Activated Receptor 2. ACS Chemical Biology, 2017, 12, 1217-1226.	3.4	34
69	Mapping transmembrane residues of proteinase activated receptor 2 (PAR 2) that influence ligand-modulated calcium signaling. Pharmacological Research, 2017, 117, 328-342.	7.1	8
70	Exploiting a novel conformational switch to control innate immunity mediated by complement protein C3a. Nature Communications, 2017, 8, 351.	12.8	30
71	Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists. Scientific Reports, 2016, 6, 24575.	3.3	38
72	PAR2 Modulators Derived from GB88. ACS Medicinal Chemistry Letters, 2016, 7, 1179-1184.	2.8	12

#	Article	IF	Citations
73	Potent Small Agonists of Protease Activated Receptor 2. ACS Medicinal Chemistry Letters, 2016, 7, 105-110.	2.8	16
74	Benzylamide antagonists of protease activated receptor 2 with anti-inflammatory activity. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 986-991.	2.2	4
75	Short Hydrophobic Peptides with Cyclic Constraints Are Potent Glucagon-like Peptide-1 Receptor (GLP-1R) Agonists. Journal of Medicinal Chemistry, 2015, 58, 4080-4085.	6.4	38
76	Potent complement C3a receptor agonists derived from oxazole amino acids: Structureâ€“activity relationships. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 5604-5608.	2.2	7
77	Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2. Journal of Chemical Information and Modeling, 2015, 55, 2079-2084.	5.4	10
78	Biased signalling and proteinaseâ€activated receptors (<scp>PAR</scp>s): targeting inflammatory disease. British Journal of Pharmacology, 2014, 171, 1180-1194.	5.4	153
79	Pathwayâ€selective antagonism of proteinase activated receptor 2. British Journal of Pharmacology, 2014, 171, 4112-4124.	5.4	54
80	Inflammatory Responses Induced by Lipopolysaccharide Are Amplified in Primary Human Monocytes but Suppressed in Macrophages by Complement Protein C5a. Journal of Immunology, 2013, 191, 4308-4316.	0.8	70
81	C5aR and C3aR antagonists each inhibit dietâ€induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling. FASEB Journal, 2013, 27, 822-831.	0.5	112
82	Dietâ€induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism. FASEB Journal, 2013, 27, 4757-4767.	0.5	93
83	Downsizing a human inflammatory protein to a small molecule with equal potency and functionality. Nature Communications, 2013, 4, 2802.	12.8	28
84	PAR2-induced inflammatory responses in human kidney tubular epithelial cells. American Journal of Physiology - Renal Physiology, 2013, 304, F737-F750.	2.7	40
85	An antagonist of human protease activated receptorâ€2 attenuates PAR2 signaling, macrophage activation, mast cell degranulation, and collagenâ€induced arthritis in rats. FASEB Journal, 2012, 26, 2877-2887.	0.5	91
86	An Inhibitor of Phospholipase A2 Group IIA Modulates Adipocyte Signaling and Protects Against Diet-Induced Metabolic Syndrome in Rats. Diabetes, 2012, 61, 2320-2329.	0.6	47
87	Antagonism of Protease-Activated Receptor 2 Protects against Experimental Colitis. Journal of Pharmacology and Experimental Therapeutics, 2012, 340, 256-265.	2.5	83
88	A Comparative Study of Impedance versus Optical Label-Free Systems Relative to Labelled Assays in a Predominantly Gi Coupled GPCR (C5aR) Signalling. Biosensors, 2012, 2, 273-290.	4.7	14
89	Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110). British Journal of Pharmacology, 2012, 165, 1413-1423.	5.4	96
90	Structure, function and pathophysiology of protease activated receptors. , 2011, 130, 248-282.		315

#	Article	IF	Citations
91	Profiling Gene Expression Induced by Protease-Activated Receptor 2 (PAR2) Activation in Human Kidney Cells. PLoS ONE, 2010, 5, e13809.	2.5	43
92	Novel Agonists and Antagonists for Human Protease Activated Receptor 2. Journal of Medicinal Chemistry, 2010, 53, 7428-7440.	6.4	91
93	A refined agonist pharmacophore for protease activated receptor 2. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5552-5557.	2.2	20
94	Validation of Messenger Ribonucleic Acid Markers Differentiating Among Human Acute Respiratory Distress Syndrome Subgroups in an Ovine Model of Acute Respiratory Distress Syndrome Phenotypes. Frontiers in Medicine, 0, 9, .	2.6	2